Pfizer/Eyetech Touting Macugen As Early Treatment Ahead Of Lucentis Entry
Executive Summary
Pfizer/Eyetech will attempt to position Macugen as an early treatment for age-related macular degeneration ahead of expected competition in the market
You may also be interested in...
Genentech Could Initiate Lucentis Rolling BLA Filing As Early As December
Genentech could begin a rolling BLA filing for its neovascular (wet) age-related macular degeneration therapy Lucentis (ranibizumab) as early as December if the company is granted fast-track designation by FDA
Genentech Could Initiate Lucentis Rolling BLA Filing As Early As December
Genentech could begin a rolling BLA filing for its neovascular (wet) age-related macular degeneration therapy Lucentis (ranibizumab) as early as December if the company is granted fast-track designation by FDA
Lucentis Fits Genentech’s Small Market/High Need Business Model
The macular degeneration treatment Lucentis (ranibizumab) fits the Genentech business model of developing products for small markets with high unmet medical need, the company said